Fore Bio

Fore Biotherapeutics

This precision oncology company develops targeted therapies for patients with unaddressed cancer mutations, including a specific BRAF inhibitor for advanced solid tumours.

D3 Bio

This biotechnology company develops precision medicines and oncology therapeutics for patients with cancer and immunological conditions.

Frontier Medicines

This biopharmaceutical company develops small-molecule precision medicines targeting undruggable proteins for patients with cancer and immunological diseases.

iOnctura

The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.

Carrick Therapeutics

This biopharmaceutical company develops precision oncology therapies for patients with aggressive cancers, focusing on small molecules and inhibitors for solid tumours.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Accent Therapeutics

This biopharmaceutical company develops small molecule precision therapies for patients with various types of cancer.

NeoPhore

This company develops small-molecule immuno-oncology medicines that inhibit DNA mismatch repair to stimulate immune responses against cancer for patients with solid tumours.